Cargando…
Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288723/ http://dx.doi.org/10.1186/2051-1426-2-S3-P69 |
| _version_ | 1782352013688832000 |
|---|---|
| author | Ferris, Robert L Cohen, Ezra Gash, Kelly Whiting, Sam Manjarrez, Kristi Dietsch, Greg Hershberg, Robert Bryan, James Kyle |
| author_facet | Ferris, Robert L Cohen, Ezra Gash, Kelly Whiting, Sam Manjarrez, Kristi Dietsch, Greg Hershberg, Robert Bryan, James Kyle |
| author_sort | Ferris, Robert L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288723 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887232015-01-15 Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) Ferris, Robert L Cohen, Ezra Gash, Kelly Whiting, Sam Manjarrez, Kristi Dietsch, Greg Hershberg, Robert Bryan, James Kyle J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288723/ http://dx.doi.org/10.1186/2051-1426-2-S3-P69 Text en Copyright © 2014 Ferris et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Ferris, Robert L Cohen, Ezra Gash, Kelly Whiting, Sam Manjarrez, Kristi Dietsch, Greg Hershberg, Robert Bryan, James Kyle Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title_full | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title_fullStr | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title_full_unstemmed | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title_short | Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) |
| title_sort | active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with tlr8 agonist vtx-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (scchn) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288723/ http://dx.doi.org/10.1186/2051-1426-2-S3-P69 |
| work_keys_str_mv | AT ferrisrobertl active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT cohenezra active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT gashkelly active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT whitingsam active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT manjarrezkristi active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT dietschgreg active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT hershbergrobert active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn AT bryanjameskyle active8arandomizeddoubleblindplacebocontrolledstudyofchemotherapypluscetuximabincombinationwithtlr8agonistvtx2337inpatientswithrecurrentormetastaticsquamouscellcarcinomaoftheheadandneckscchn |